LAVANCE L. NORTHINGTON, MBA
Mr. Northington brings more than 25 years of entrepreneurial and corporate leadership experience. His career has focused on strategic partnership, corporate development and operational efficiencies in founding and growing several start-up technology companies. Most recently, Mr. Northington co founded and was President at Soberlink, Inc., developer of the worlds first handheld, wireless breathalyzer. Mr. Northington has held leadership roles at several mid market and start up firms as well as senior level sales positions at Fortune 100 companies like Avaya, ATT and Verizon Business. He earned his M.B.A from Oregon State University.
GARY GUST, Ph.D.
Gary has designed and managed the development of several clinical laboratory automation instruments. Most notably, as VP of Systems Development at Osmetech (Now Genmark), he led a team that developed the highly regarded XT-8 DNA detection platform, which received FDA approval and won a Medical Design Excellence Award, an R&D 100 Award, and an Innovations in Healthcare ABBY Award. To date, Gary has designed and developed more than a dozen different systems that have been FDA approved.
SYLVIA NORMAN, Ph.D.
With over 25 experience in molecular biology R&D, Sylvia has designed, developed and validated diagnostic assays and processed clinical specimens for diagnostic testing for Gen-Probe (Hologic), DermTech, Nanogen, Stratagene (Agilent) and Althea Technologies (Ajinomoto Althea) to name a few. With 11 issued patents relating to diagnostic detection of infectious diseases, Sylvia has developed a keen expertise for bringing POC molecular diagnostic assays to market.
YUHWA LO, Ph.D.
Dr. Lo is the lead inventor of this technology. As a Professor of Electrical Computer Engineering at UCSD, Dr. Lo heads a team of 17 Ph.D and Postdoc researchers where their focus is on biomedical devices and systems, bioelectronics, microfluidics, nanophotonics, and semiconductor nanoscaled devices. He also serves as the Director of the Nano3 Facility (Nanoscience, Nanoengineering, and Nanomedicine). Dr Lo has published nearly 400 technical papers, 10 book chapters, been awarded 26 patents and has spun-out several technologies from his lab that have been commercialized.
ROBERT THOMPSON, MBA
Currently CEO of Emerge Diagnostics, Robert has been CEO of 2 previous venture-backed firms that achieved considerable shareholder value with their exits. Robert has been employed at the "C" level for over 20 years and brings a great deal of operational experience in growing small biotech companies to exit. As the CEO, he architected the sale of eScreen to Allere.
JOHN RADAK, MBA
Currently CFO at publicly traded ArborGen, Inc., John is a well respected Wall Street CFO with public and private experience at global, mid-size medical, manufacturing, life sciences, CPG, technology and ecommerce companies. John has had similar positions at Quidel and Life Technologies and is known for transforming businesses to create value.
ALEXANDER KHALESSI, MD, MS
A board-certified neurosurgeon, Dr. Khalessi is also an associate Professor of Surgery and Neurosciencesat the University of California @ San Diego. Dr. Khalessi is the vice chairman of clinical affairs, the director of endovascular neurosurgery and surgical director of neurocritical care. Dr. Khalessi is the only neurosurgeon to serve on the Interventional Advisory Panel for the StrokeNetSteering Committee and also leads the National Football League's (NFL) Unaffiliated Neurotrauma Consultant (UNC) Program in the Southern California region.